ELI LILLY AND COMPANY vs NOVO NORDISK A/S, two Drug Manufacturers stocks. A side-by-side on valuation, growth, margins, returns, and what each price is betting.
Where LLY and NVO diverge most: on ev/ebitda, LLY reads 550.3 and NVO reads 8.9; on return on invested capital, LLY reads 1.4% and NVO reads 30.8%. The rest of the comparable metrics sit closer together. The bull and bear cases for each are in their full reports below.
| Metric | LLY | NVO |
|---|---|---|
| Price | $1178.18 | $38.62 |
| Market cap | $1.11T | $171.6B |
| Sector | Drug Manufacturers | Drug Manufacturers |
| Stage | Mature | Growth |
| Implied growth (priced in) | +22.2% | — |
| P/E | 39.5 | 11.4 |
| P/B | 32.74 | 6.01 |
| P/S | 13.92 | 3.78 |
| EV/EBITDA | 550.3 | 8.9 |
| Revenue growth | +49.9% | +22.1% |
| Gross margin | — | 81.0% |
| Operating margin | — | 41.3% |
| Net margin | 33.5% | 33.1% |
| Return on equity | 78.8% | 52.8% |
| Return on assets | 18.8% | 18.9% |
| Return on invested capital | 1.4% | 30.8% |
| FCF yield | 1.6% | 5.0% |
| Dividend yield | 0.5% | — |
| Debt / equity | 1.62 | 0.67 |
| Current ratio | 1.35 | 0.80 |
| Altman Z (solvency) | 7.02 | 3.76 |
| Piotroski F (quality) | 7 / 9 | 3 / 9 |
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
The stronger value is highlighted per metric where one is strictly better on that single number; it is not an overall verdict on either company. For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.